Fractalkine (CX3CL1) and fractalkine receptor (CX3CR1) in squamous cell carcinoma of the tongue: Markers of nerve invasion?

被引:10
|
作者
Doumas S. [1 ,2 ]
Paterson J.C. [3 ]
Norris P.M. [1 ]
Tighe J.V. [1 ]
Newman L. [1 ]
Bisase B.S. [1 ]
Kolokotronis A.E. [4 ]
Barrett A.W. [1 ,5 ]
机构
[1] Queen Victoria Hospital NHSF Trust, East Grinstead, West Sussex
[2] Southern General Hospital, Glasgow
[3] UCL Advanced Diagnostics, London
[4] Oral Medicine & Maxillofacial Pathology, Dental School, Aristotle University, Thessaloniki
[5] Department of Histopathology, Queen Victoria Hospital NHSF Trust, Holtye Road, East Grinstead
关键词
Fractalkine; Fractalkine receptor; Oral cancer; Perineural invasion;
D O I
10.1007/s10006-014-0455-4
中图分类号
学科分类号
摘要
Conclusions: Neither fractalkine nor fractalkine receptor is a reliable surrogate marker of PNI in lingual SCC.; Purpose: Perineural invasion (PNI) in oral squamous cell carcinoma (SCC) is an independent predictor of poor prognosis. As PNI is not always identified with routine histology, a surrogate marker of PNI would improve detection and better inform treatment planning. The chemokines fractalkine (CX3CL1) and its receptor (CX3CR1) have shown such potential in other cancers, but have yet to be investigated with respect to PNI in oral SCC.; Results: Both markers labelled myofibroblasts in the stroma surrounding the tumour, various neural components, leucocytes, endothelium and salivary myoepithelial cells. Fractalkine also labelled salivary ductal epithelium, vascular smooth muscle and 12/30 SCC which showed PNI. Eight of 30 positive SCCs in which PNI was not identified were also positive for this marker. There was no statistically significant association between fractalkine staining and PNI (p = 0.273). No SCC was positive for fractalkine receptor, but immune dendritic cells within tumour islands were strongly positive, as was striated muscle.; Methods: Thirty SCCs of the tongue in which PNI was identified histologically, and 30 in which it was not, were stained for fractalkine and fractalkine receptor using polyclonal antibodies and an immunoperoxidase technique. Tumours were assessed as either positive or negative; no attempt was made to subjectively assess staining intensity or extent. © 2014, Springer-Verlag Berlin Heidelberg.
引用
收藏
页码:61 / 64
页数:3
相关论文
共 50 条
  • [21] Potential biomarkers reflecting inflammation in patients with severe periodontitis: Fractalkine (CX3CL1) and its receptor (CX3CR1)
    Balci, Nur
    Cekici, Ali
    Kurgan, Sivge
    Sahinkaya, Selin
    Serdar, Muhittin A.
    [J]. JOURNAL OF PERIODONTAL RESEARCH, 2021, 56 (03) : 589 - 596
  • [22] Expression of fractalkine (CX3CL1) and its receptor, CX3CR1, during acute and chronic inflammation in the rodent CNS
    Hughes, PM
    Botham, MS
    Frentzel, S
    Mir, A
    Perry, VH
    [J]. GLIA, 2002, 37 (04) : 314 - 327
  • [23] Role of the chemokine fractalkine (CX3CL1) and its receptor CX3CR1 in skeletal metastasis from prostate cancer
    Jamieson, Whitney L.
    Fox, Julia A.
    Fatatis, Alessandro
    [J]. CANCER RESEARCH, 2006, 66 (08)
  • [24] Polymorphisms of Fractalkine receptor CX3CR1 and plasma levels of its ligand CX3CL1 in colorectal cancer patients
    Jan Dimberg
    Olaf Dienus
    Sture Löfgren
    Anders Hugander
    Dick Wågsäter
    [J]. International Journal of Colorectal Disease, 2007, 22 : 1195 - 1200
  • [25] Fractalkine/CX3CL1 in Neoplastic Processes
    Korbecki, Jan
    Siminska, Donata
    Kojder, Klaudyna
    Grochans, Szymon
    Gutowska, Izabela
    Chlubek, Dariusz
    Baranowska-Bosiacka, Irena
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (10)
  • [26] Fractalkine/CX3CL1 in rheumatoid arthritis
    Nanki, Toshihiro
    Imai, Toshio
    Kawai, Shinichi
    [J]. MODERN RHEUMATOLOGY, 2017, 27 (03) : 392 - 397
  • [27] Relevance of the CX3CL1/fractalkine-CX3CR1 pathway in vasculitis and vasculopathy
    Kasama, Tsuyoshi
    Wakabayashi, Kuninobu
    Sato, Michihito
    Takahashi, Ryo
    Isozaki, Takeo
    [J]. TRANSLATIONAL RESEARCH, 2010, 155 (01) : 20 - 26
  • [28] CX3CL1 (fractalkine) and its receptor CX3CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin
    Staumont-Salle, Delphine
    Fleury, Sebastien
    Lazzari, Anne
    Molendi-Coste, Olivier
    Hornez, Nicolas
    Lavogiez, Celine
    Kanda, Akira
    Wartelle, Julien
    Fries, Anissa
    Pennino, Davide
    Mionnet, Cyrille
    Prawitt, Janne
    Bouchaert, Emmanuel
    Delaporte, Emmanuel
    Glaichenhaus, Nicolas
    Staels, Bart
    Julia, Valerie
    Dombrowicz, David
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2014, 211 (06): : 1185 - 1196
  • [29] CX3CL1/fractalkine and its receptor CX3CR1 regulate atopic dermatitis by controlling effector T cell retention in inflamed skin
    Staumont-Salle, D.
    Homez, N.
    Lavogiez, C.
    Kanda, A.
    Mionnet, C.
    Prawitt, J.
    Fleury, S.
    Bouchaert, E.
    Lazzari, A.
    Delaporte, E.
    Glaichenhaus, N.
    Staels, B.
    Julia, V.
    Dombrowicz, D.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 : S21 - S21
  • [30] The fractalkine receptor CX3CR1 is a key mediator of atherogenesis
    Cybulsky, MI
    Hegele, RA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2003, 111 (08): : 1118 - 1120